Mural Oncology Highlights Clinical Trials During It's Maiden Investor Day [Forbes]
Mural Oncology plc - Ordinary Shares (MURA)
Company Research
Source: Forbes
Mural Oncology (NASDAQ: MURA, $3.05, Market Capitalization $52.0 million), a clinical-stage oncology company focused on discovering and developing immunotherapies, held its first virtual Investor Day on September 26. During the Investor call, the company highlighted latestage clinical progress in its lead candidate, Nemvaleukin, and provided updates on future pipeline developments. Nemvaleukin, an engineered IL-2 cytokine, is designed to enhance anti-tumor effects while mitigating toxicity, with promising efficacy shown in combination with pembrolizumab. The company's phase 3 ARTISTRY-7 trial for platinum-resistant ovarian cancer and phase 2 ARTISTRY-6 trial for mucosal melanoma are fully enrolled, with key data readouts expected in early to mid-2025. Also, the company stated that if the hazard ratio meets the bar for success for ARTISTRY-7, the study will be declared positive, and the company will plan to file a Biologics License Application (BLA) in 2025, or the company may decide
Show less
Read more
Impact Snapshot
Event Time:
MURA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MURA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MURA alerts
High impacting Mural Oncology plc - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
MURA
News
- Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Mural Oncology Announces Publication Highlighting Promising Clinical Antitumor Activity Shown in its ARTISTRY-1 Clinical Trial of Nemvaleukin, its Lead Engineered Fusion Protein, in the Journal for ImmunoTherapy of CancerGlobeNewswire
- Mural Oncology Announces Third Quarter 2024 Financial Results and Provides Update on Pipeline ProgressGlobeNewswire
- Mural Oncology plc (NASDAQ: MURA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $18.00 price target on the stock.MarketBeat
- Mural Oncology to Participate in Two Upcoming Investor ConferencesGlobeNewswire
MURA
Sec Filings
- 12/23/24 - Form 144
- 11/20/24 - Form EFFECT
- 11/14/24 - Form SC
- MURA's page on the SEC website